The Role of Neoadjuvant Chemotherapy in the Treatment of Nasopharyngeal Carcinoma: A Multi-institutional Retrospective Study (KROG 11-06) Using Propensity Score Matching Analysis
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). Materials and Methods A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed. Results After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). Conclusion This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.
Abstract
Purpose We compared the treatment results and toxicity in nasopharyngeal carcinoma (NPC) patients treated with concurrent chemotherapy (CCRT) alone (the CRT arm) or neoadjuvant chemotherapy followed by CCRT (the NCT arm). Materials and Methods A multi-institutional retrospective study was conducted to review NPC patterns of care and treatment outcome. Data of 568 NPC patients treated by CCRT alone or by neoadjuvant chemotherapy followed by CCRT were collected from 15 institutions. Patients in both treatment arms were matched using the propensity score matching method, and the clinical outcomes were analyzed. Results After matching, 300 patients (150 patients in each group) were selected for analysis. Higher 5-year locoregional failure-free survival was observed in the CRT arm (85% vs. 72%, p=0.014). No significant differences in distant failure-free survival (DFFS), disease-free survival (DFS), and overall survival were observed between groups. In subgroup analysis, the NCT arm showed superior DFFS and DFS in stage IV patients younger than 60 years. No significant difference in compliance and toxicity was observed between groups, except the radiation therapy duration was slightly shorter in the CRT arm (50.0 days vs. 53.9 days, p=0.018). Conclusion This study did not show the superiority of NCT followed by CCRT over CCRT alone. Because NCT could increase the risk of locoregional recurrences, it can only be considered in selected young patients with advanced stage IV disease. The role of NCT remains to be defined and should not be viewed as the standard of care.
참고문헌 (24)
- Jeon YK, "Molecular characterization of Epstein-Barr virus and oncoprotein expression in nasopharyngeal carcinoma in Korea", Head Neck, 26, pp.573~583 (2004)
- Kim YJ, "Immunohistochemical study identifying prognostic biomolecular markers in nasopharyngeal carcinoma treated by radiotherapy", Head Neck, 33, pp.1458~1466 (2011)
- Annual report of cancer statistics in Korea in 2011, "The Korea Central Cancer Registry, National Cancer Center", Ministry of Health and Welfare, ~ (2011)
- 이남권, "이차원방사선치료를 시행한 코인두암 환자의 장기 추적 결과 및 예후인자 분석", Radiation oncology journal, 28(4), pp.193~204 (2010), 대한방사선종양학회
- Spratt DE, "Current and emerging treatment options for nasopharyngeal carcinoma", Onco Targets Ther, 5, pp.297~308 (2012)
- 김연실, "Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea", Cancer Research and Treatment, 40(4), pp.155~163 (2008), 대한암학회
- Al-Sarraf M, "Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer : phase III randomized Intergroup study 0099", J Clin Oncol, 16, pp.1310~1317 (1998)
- Lin JC, "Phase III study of concurrent chemoradiotherapy versus radiotherapy alone for advanced nasopharyngeal carcinoma : positive effect on overall and progression-free survival", J Clin Oncol, 21, pp.631~637 (2003)
- Chan AT, "Overall survival after concurrent cisplatin-radiotherapy compared with radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma", J Natl Cancer Inst, 97, pp.536~539 (2005)
- 공문규, "Comparison of survival rates between patients treated with conventional radiotherapy and helical tomotherapy for head and neck cancer", Radiation oncology journal, 31(1), pp.1~11 (2013), 대한방사선종양학회
- Hui EP, "Randomized phase II trial of concurrent cisplatin-radiotherapy with or without neoadjuvant docetaxel and cisplatin in advanced nasopharyngeal carcinoma", J Clin Oncol, 27, pp.242~249 (2009)
- Bae WK, "Phase II study of docetaxel, cisplatin, and 5-FU induction chemotherapy followed by chemoradiotherapy in locoregionally advanced nasopharyngeal cancer", Cancer Chemother Pharmacol, 65, pp.589~595 (2010)
- Ekenel M, "Induction chemotherapy with docetaxel and cisplatin is highly effective for locally advanced nasopharyngeal carcinoma", Oral Oncol, 47, pp.660~664 (2011)
- Fountzilas G, "Induction chemotherapy followed by concomitant radiotherapy and weekly cisplatin versus the same concomitant chemoradiotherapy in patients with nasopharyngeal carcinoma : a randomized phase II study conducted by the Hellenic Cooperative Oncology Group(HeCOG)with biomarker evaluation", Ann Oncol, 23, pp.427~435 (2012)
- Liang ZG, "Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy with or with-out adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma : meta-analysis of 1, 096 patients from 11randomized controlled trials", Asian Pac J Cancer Prev, 14, pp.515~521 (2013)
- 위찬우, "Locoregionally advanced nasopharyngeal carcinoma treated with intensity-modulated radiotherapy plus concurrent weekly cisplatin with or without neoadjuvant chemotherapy", Radiation oncology journal, 33(2), pp.98~108 (2015), 대한방사선종양학회
- Thompson LD, "Update on nasopharyngeal carcinoma", Head Neck Pathol, 1, pp.81~86 (2007)
- Miller AB, "Reporting results of cancer treatment", Cancer, 47, pp.207~214 (1981)
- Trotti A, "CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment", Semin Radiat Oncol, 13, pp.176~181 (2003)
- Kong L, "Neoadjuvant chemotherapy followed by concurrent chemoradiation for locoregionally advanced nasopharyngeal carcinoma : interim results from 2 prospective phase 2 clinical trials", Cancer, 119, pp.4111~4118 (2013)
- Ma J, "Results of a prospective randomized trial comparing neoadjuvant chemotherapy plus radiotherapy with radiotherapy alone in patients with locoregionally advanced nasopharyngeal carcinoma", J Clin Oncol, 19, pp.1350~1357 (2001)
- Hareyama M, "A prospective, randomized trial comparing neoadjuvant chemotherapy with radiotherapy alone in patients with advanced nasopharyngeal carcinoma", Cancer, 94, pp.2217~2223 (2002)
- Zhang LN, "Effect of taxanes-based induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma : A large scale propensity-matched study", Oral Oncol, 51, pp.950~956 (2015)
- Vermorken JB, "Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer", N Engl J Med, 357, pp.1695~1704 (2007)